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Adoptive transfer of autologous dendritic cells (DC)
presenting tumor-associated antigens initiate and sustain an
immune response which eradicate murine malignancies.
Based on these observations, several clinical trials are in
progress testing safety and efficacy with encouraging pre-
liminary reports. In these approaches, ex vivo incubation of
DC with a source of tumor antigens is required to load the
relevant antigenic epitopes on the adequate antigen
presenting molecules. Recent data show that in some
instances exogenous DC artificially injected into malignant
tissue or endogenous DC attracted to the tumor nodule by
means of gene transfer of GM-CSF and CD40L into malig-
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Intratumoral release of DC for
immunotherapy
The use of ex vivo differentiated dendritic cells (DC) to
induce or amplify antitumor immune responses thera-
peutically is finding its way into the clinic with encour-
aging results in pilot studies.1 DC have unique capabili-
ties to induce T cell-dependent immunity due to their
outstanding array of membrane MHC antigen presenting
molecules, cytokines, costimulatory factors and ability to
traffick into lymphoid organs.2–4 In murine models, ex
vivo gene transfer strategies have been used to provide
DC with the genes coding for cytokines to enhance their
immune adjuvant activity further5–9 or with genes coding
for tumor rejection antigens in order to present them to
relevant T cells.1,10
Different sorts of genes and vectors have been used to
transduce DC with tumor antigens and notable success
has been achieved with recombinant adenovirus11–13 and
naked or liposome formulated RNA.14,15 Alternatively,
tumor antigens can be loaded on to DC MHC antigen
presenting molecules by pulsing the cells with synthetic
peptides,16–18 purified proteins,19 tumor lysates,18,20 or
crude eluted peptides from malignant cells.21 Coculture
of DC with tumor cell lines can also result in sufficient
antigen uptake by DC to stimulate CTL-mediated
immune responses able to generate antitumor protective
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nant cells result in efficacious antitumor immunity. In the
case of intratumoral injection of DC the procedure is curative
only if DC had been genetically engineered to produce IL-
12, IL-6 or to express CD40L. Evidence has been obtained
showing that intratumoral DC can capture and process
tumor antigens to be presented to T-lymphocytes. Although
the exact mechanisms of tumor antigen acquisition by DC
are still unclear, available data suggest a role for heat shock
proteins released from dying malignant cells and for the
internalization of tumor-derived apoptotic bodies. Roles for
tumor necrosis versus apoptosis are discussed in light of the
‘danger theory’. Gene Therapy (2000) 7, 1167–1170.
immunity.22 Injection of immature cultured DC with
irradiated tumor cell lines also induced protective, but
low levels of therapeutic immunity.23 Moreover, intratu-
moral injection of DC was not therapeutically efficacious
(unless the tumor was surgically removed), when specific
antitumor immunity developed.
Although intratumoral injection of DC by itself has
very modest therapeutic results,8 two recent reports have
shown that if DC are engineered to secrete IL-12 with
recombinant retrovirus7 or adenovirus,8 they induce very
intense therapeutic antitumor immunity against the
treated malignant nodule and coexisting noninjected
tumor nodules. The same has been observed when intra-
tumorally injected DC have been modified with an
adenovirus coding for CD40L.24 The antitumor effector
cells in either case were primarily CD8+ cytotoxic T cells,8
presumably primed by the adoptively transferred DC,
which had actively migrated into T cell areas of draining
lymph nodes after picking up the tumor antigens from
malignant cells.7,8 Intratumoral injection of artificially cul-
tured DC is not the only possibility, since endogenous
DC can be attracted to the tumor tissue with the help of
specific chemotactic factors. For instance, tumors trans-
fected with GM-CSF become infiltrated by DC and, if the
tumor is cotransfected with CD40L to activate and
mature these infiltrating DC, very powerful antitumor
immune responses are unleashed.25
IL-12 is a cytokine which induces IFNg production
from many cell types such as T cells, NK cells26 and den-
dritic cells.27 It has been shown to be important to differ-
entiate responding T helper cells to a Th1 phenotype.
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Both the recombinant protein and its gene transduced
into tumors have shown remarkable therapeutic activity
due not only to enhancement of antitumor cellular
immune responses but also to impairment of tumor
angiogenesis.28,29 It is clear that IL-12 secreted by intra-
tumorally injected DC greatly up-regulates the antitumor
properties of DC.7,8 Several nonmutually exclusive mech-
anisms could account for this beneficial effect: (1) IL-12-
secreting DC could prime a more intense CTL and Th1
response upon arrival at lymphoid organs; (2) IL-12 can
stimulate DC in an autocrine fashion to acquire certain
functions such as IFNg secretion;27,30,31 (3) IL-12 can act
on the tumor stroma either directly or through secondary
cytokines to promote inflammatory changes in endo-
thelium to promote homing of effector tumor-killer T
cells32,33 or to impair tumor angiogenesis.34
To trigger the immune system properly, DC should be
activated. Indeed, DC derived from cultures of mono-
cytes or bone marrow precursors with GM-CSF and IL-
4 display a so-called immature phenotype. In this stage
DC avidly acquire antigens, but are poor at stimulating
specific T cells.3,4 Certain stimuli are known to reverse
these properties in a process named maturation which
encompasses the orchestrated regulation of multiple
genes. Many factors promoting DC maturation have been
identified and can be classified into three groups: (1) bac-
terial or viral components (ie bacterial DNA,35 Lypopoly-
saccharide,36 dRNA,37 etc); (2) endogenous proinflamma-
tory factors (ie IL-1, TNFa,38 IL-12,30 or possibly released
heat shock proteins39); (3) DC interaction with activated
T helper cells providing stimulation through surface pro-
teins such as CD40 and/or MHC-class II.40,41 An imma-
ture phenotype of DC to be injected in the tumors was
chosen to allow DC to take up and present antigen from
tumor cells and then migrate into lymph nodes, but a
formal proof for this concept has not yet been published.
Stimulation by gene transferred IL-12 and CD40L is prob-
ably critical in such settings to enhance certain DC func-
tions which are necessary for therapeutic efficacy. It has
been published recently that intratumoral injection of DC
engineered with recombinant adenovirus to secrete IL-7
also displayed potent antitumor properties.9 In this case
the main effect of the IL-7 transgene is likely the expan-
sion of antitumor T cell clones, although relevant direct
or indirect effects of IL-7 on DC cannot be excluded.
Mechanisms of antigen capture
A key issue is the mechanism of antigen uptake from
tumor cells. Antigen capture inside the tumor tissue has
been proved by recovering DC from the malignant nod-
ule and by testing their ability to activate in vitro T cells
specific for tumor antigens and to immunize naive mice
for CTL induction.25 In this setting DC were found to
internalize TUNEL+ apoptotic material, but although this
mechanism has been proposed to be important for anti-
gen transfer in in vitro,25 the finding has not been stressed
since there was no proof that apoptotic bodies were from
tumor cells. Other studies suggest that cells dying
through necrosis rather than by apoptosis are the most
immunogenic, since they leave their remains in a fashion
prone to pass their antigens into DC.42 In fact, release of
proteins such as hsp-70 by dying cells has been shown to
be very efficient means of antigen transfer to the antigen
presenting pathways of DC.43,44 The mechanisms of
action of hsp70 are still elusive, although one possibility
is the proposed ability of hsp to chaperone immunogenic
peptides into APC.45 In addition, factors released by
dying cells can activate DC maturation, especially when
not cleared by scavenger macrophages.46,47
In most tissues natural cell death occurs via apoptosis.
Such a process is likely ignored by the immune system
or may be involved in the induction of tolerance to nor-
mal self components.48 In contrast, we propose the con-
cept of a stressful cell death, in which cells, regardless of
whether they are dying by apoptosis or necrosis, release
these endogenous DC activators, which are known to be
overexpressed in cells under stress.49 Accordingly, cells
dying in an environment containing microbial compo-
nents or proinflammatory cytokines will also end up with
their antigens being presented in an immunogenic
fashion. This is consistent with the overall concepts of the
danger theory proposed by Matzinger,50,51 according to
which naive T cell precursors only become activated if
they see their antigen on an activated (or mature) den-
dritic cell. Injection of DC in a tumor mass can trigger
such stressful cell death events by mechanical damage
caused by the needle and the injected fluid. In addition,
DC can execute direct cytotoxicity against certain tumor
targets52 and/or they can locally activate NK cells.53
Interestingly, IL-12 gene transfer can increase these NK
cell activating properties of DC. Therefore, strategies to
enhance tissue necrosis in the tumor mass before artificial
release of DC should be evaluated to enhance efficacy.
Tumor masses contain normal components in the
stroma and malignant cells share most of their protein
sequences with normal cells. This may raise concern
about the risk of triggering autoimmunity against normal
self tissue. Nonetheless, careful monitoring of mice suc-
cessfully treated by intratumoral injection of gene modi-
fied DC have not shown signs of autoimmune disease.8
Intratumoral injection of DC engineered to produce IL-
12 is now reaching the clinical arena due to its feasibility
and preclinical results. The outcome of the trials will
show if this promising approach is really safe and effi-
cacious. In addition, repeated intratumoral injection of
DC is feasible and, as long as there is enough injectable
malignant tissue left, repetitive boost of antitumor
immunity should be possible.
Conclusion
The explosion in the molecular identification of tumor
antigens offers new hope for construction of successful
vaccines for cancer. However, even now it seems clear
that single antigens will not suffice for effective clearance
of tumors consisting of polyclonal cells with a range of
antigens expressed and lost. One trend has been the con-
struction of poly-epitope vaccines delivered by DNA or
viral vector-mediated vaccination approaches. However,
even this a` la carte construction of vaccine components
leaves too much to chance and runs the risk of leaving
out crucial antigenic components which may not even
have been identified yet. Surely it is better to leave the
dendritic cells to sample and display the antigens that
may be most relevant to raising effective antitumor
responses directly in vivo. Although our molecular skills
at cloning tumor antigens are proceeding impressively
fast, it seems more sensible to facilitate the entry of DC
into tumors (either by gene modification of the tumor
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serve themselves from the feast of potential antigens than
to assume that we can construct a better menu for
them ourselves.
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